Location of recurrent cardiovascular events and anticardiolipin antibodies.
Aged
Antibodies, Anticardiolipin
/ immunology
Cerebrovascular Disorders
/ immunology
Coronary Artery Disease
/ immunology
Female
Humans
Ischemia
/ epidemiology
Ischemic Stroke
/ epidemiology
Lower Extremity
/ blood supply
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction
/ epidemiology
Peripheral Arterial Disease
/ immunology
Proportional Hazards Models
Recurrence
Registries
IgG
IgM
anticardiolipin antibodies
ischaemic event
myocardial infarction
symptomatic artery disease
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
22
02
2021
received:
22
01
2021
accepted:
23
02
2021
pubmed:
6
3
2021
medline:
21
12
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
The relationship between anticardiolipin (aCL) antibodies and cardiovascular events is uncertain and may vary according to arterial location. FRENA is an ongoing registry of stable outpatients with symptomatic coronary artery disease (CAD), cerebrovascular disease (CVD) or peripheral artery disease (PAD). The rate of subsequent ischaemic events was cross-referenced with the presence of aCL antibodies (any isotype, IgG or IgM). As of June 2017, 1387 stable outpatients were recruited. Of these, 120 (8.7%) showed positive levels of aCL antibodies. Over an average follow-up of 18 months, 250 patients developed subsequent events: 101 myocardial infarction, 57 ischaemic stroke and 92 critical leg events. Patients with positive aCL antibodies had a higher risk of distal artery events (a composite of ischaemic stroke or critical leg events) than patients with undetectable or low levels (rate ratio: 1.66; 95% CI: 1.07-2.60). However, an association with central coronary events was not found. The multivariate Cox analysis after adjustment for relevant clinical covariates showed that positivity of aCL antibodies is an independent risk factor for distal events (hazard ratio: 1.60; 95% CI: 1.01-2.55; P < .05). Positivity of aCL antibodies is associated with an increased risk of subsequent distal artery ischaemic events (cerebral or leg arteries) but not coronary artery events. Anticardiolipin antibodies appear to have a different relationship on the localisation of ischaemic events in patients with symptomatic artery disease.
Sections du résumé
BACKGROUND
BACKGROUND
The relationship between anticardiolipin (aCL) antibodies and cardiovascular events is uncertain and may vary according to arterial location.
MATERIALS AND METHODS
METHODS
FRENA is an ongoing registry of stable outpatients with symptomatic coronary artery disease (CAD), cerebrovascular disease (CVD) or peripheral artery disease (PAD). The rate of subsequent ischaemic events was cross-referenced with the presence of aCL antibodies (any isotype, IgG or IgM).
RESULTS
RESULTS
As of June 2017, 1387 stable outpatients were recruited. Of these, 120 (8.7%) showed positive levels of aCL antibodies. Over an average follow-up of 18 months, 250 patients developed subsequent events: 101 myocardial infarction, 57 ischaemic stroke and 92 critical leg events. Patients with positive aCL antibodies had a higher risk of distal artery events (a composite of ischaemic stroke or critical leg events) than patients with undetectable or low levels (rate ratio: 1.66; 95% CI: 1.07-2.60). However, an association with central coronary events was not found. The multivariate Cox analysis after adjustment for relevant clinical covariates showed that positivity of aCL antibodies is an independent risk factor for distal events (hazard ratio: 1.60; 95% CI: 1.01-2.55; P < .05).
CONCLUSIONS
CONCLUSIONS
Positivity of aCL antibodies is associated with an increased risk of subsequent distal artery ischaemic events (cerebral or leg arteries) but not coronary artery events. Anticardiolipin antibodies appear to have a different relationship on the localisation of ischaemic events in patients with symptomatic artery disease.
Substances chimiques
Antibodies, Anticardiolipin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13533Investigateurs
Aguilar E
(A)
Alcalá-Pedrajas Jn
(AP)
Alvarez Lr
(A)
Arnedo G
(A)
Coll R
(C)
García-Díaz A
(GD)
López-Jiménez L
(LJ)
Monreal M
(M)
Pascual Mt
(P)
Sahuquillo Jc
(S)
Muñoz-Torrero Jf
(MT)
Sanclemente C
(S)
Suriñach Jm
(S)
Toril J
(T)
Yeste M
(Y)
Informations de copyright
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563-e595.
Bili A, Moss AJ, Francis CW, Zareba W, Watelet LF, Sanz I. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic factors, and recurrent coronary events investigators. Circulation. 2000;102(11):1258-1263.
Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019;10:941.
Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576-584.
Gavier B, Vazquez F, Gandara E. Antiphospholipid antibodies and lower extremity peripheral arterial disease - a systematic review and meta-analysis. Vasa. 2016;45(4):325-330.
Merashli M, Bucci T, Pastori D, et al. Antiphospholipid antibodies and lower extremity peripheral artery disease: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(6):1291-1298.
Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke. 2007;38(10):2698-2705.
Bernaudo D, Coll R, Sanchez Munoz-Torrero JF, et al. Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease. Atherosclerosis. 2013;229(1):258-262.
Barba R, Bisbe J, Pedrajas JNA, et al. Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA registry. Eur J Cardiovasc Prev Rehabil. 2009;16(4):457-463.
Garcia-Diaz AM, Marchena PJ, Toril J, et al. Alcohol consumption and outcome in stable outpatients with peripheral artery disease. J Vasc Surg. 2011;54(4):1081-1087.
Alvarez LR, Balibrea JM, Surinach JM, et al. Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease. Eur J Prev Cardiol. 2013;20(3):486-495.
Sanchez Munoz-Torrero JF, Rico-Martin S, Alvarez LR, Aguilar E, Alcala JN, Monreal M. Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis. 2018;276:10-14.
Munoz-Torrero JFS, Zamorano J, Rico-Martin S, et al. Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. Atherosclerosis. 2020;292:84-89.
Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40(1):35-53.
Chighizola CB, Andreoli L, de Jesus GR, Banzato A, Pons-Estel GJ, Erkan D. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus. 2015;24(9):980-984.
Puisieux F, de Groote P, Masy E, et al. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease. Am J Med. 2000;109(8):635-641.
Vila P, Hernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72(2):209-213.
Ruffatti A, Olivieri S, Tonello M, et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost. 2008;6(10):1693-1696.
Selmi C, De Santis M, Battezzati PM, et al. Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. Int J Cardiol. 2020;300:209-213.
Pastori D, Bucci T, Triggiani M, et al. Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. Autoimmun Rev. 2019;18(5):519-525.
Nazir S, Tachamo N, Lohani S, Hingorani R, Poudel DR, Donato A. Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review. Coron Artery Dis. 2017;28(4):332-335.
Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308(16):1660-1667.
Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994-2004.
Jashari F, Ibrahimi P, Nicoll R, Bajraktari G, Wester P, Henein MY. Coronary and carotid atherosclerosis: similarities and differences. Atherosclerosis. 2013;227(2):193-200.
Narula N, Dannenberg AJ, Olin JW, et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol. 2018;72(18):2152-2163.
Yin D, Matsumura M, Rundback J, et al. Comparison of plaque morphology between peripheral and coronary artery disease (from the CLARITY and ADAPT-DES IVUS substudies). Coron Artery Dis. 2017;28(5):369-375.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244-255.